BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mahon BE, Hsu K, Karumuri S, Kaplan SL, Mason EO, Pelton SI. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens. Vaccine. 2006;24:2514-2520. [PMID: 16417951 DOI: 10.1016/j.vaccine.2005.12.025] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Omori R, Cowling BJ, Nishiura H. How is vaccine effectiveness scaled by the transmission dynamics of interacting pathogen strains with cross-protective immunity? PLoS One 2012;7:e50751. [PMID: 23226374 DOI: 10.1371/journal.pone.0050751] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
2 Park SY, Van Beneden CA, Pilishvili T, Martin M, Facklam RR, Whitney CG. Invasive Pneumococcal Infections among Vaccinated Children in the United States. The Journal of Pediatrics 2010;156:478-483.e2. [DOI: 10.1016/j.jpeds.2009.10.008] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 3.6] [Reference Citation Analysis]
3 Urueña A, Pippo T, Betelu MS, Virgilio F, Giglio N, Gentile A, Jimenez SG, Jáuregui B, Clark AD, Diosque M, Vizzotti C. Cost-effectiveness analysis of the 10- and 13-valent pneumococcal conjugate vaccines in Argentina. Vaccine 2011;29:4963-72. [PMID: 21621575 DOI: 10.1016/j.vaccine.2011.04.111] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
4 Zhuo F, Xiao M, Kong F, Oftadeh S, Zhou F, Zhang J, Gilbert GL. Prevalence and genetic diversity of pneumococcal serogroup 6 in Australia. Clin Microbiol Infect 2011;17:1246-53. [PMID: 20950338 DOI: 10.1111/j.1469-0691.2010.03404.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
5 Trotter CL, Mcvernon J, Ramsay ME, Whitney CG, Mulholland EK, Goldblatt D, Hombach J, Kieny M. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae. Vaccine 2008;26:4434-45. [DOI: 10.1016/j.vaccine.2008.05.073] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
6 Ishimine P. Risk Stratification and Management of the Febrile Young Child. Emergency Medicine Clinics of North America 2013;31:601-26. [DOI: 10.1016/j.emc.2013.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
7 Lockhart SP, Hackell JG, Fritzell B. Pneumococcal conjugate vaccines: emerging clinical information and its implications. Expert Review of Vaccines 2014;5:553-64. [DOI: 10.1586/14760584.5.4.553] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Mezones-holguin E, Canelo-aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-palza S, Hernandez AV, Vega-porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ. Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru. Vaccine 2015;33:A154-66. [DOI: 10.1016/j.vaccine.2014.12.039] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
9 Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis 2013;17:e364-73. [PMID: 23416209 DOI: 10.1016/j.ijid.2013.01.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
10 Picón T, Alonso L, García Gabarrot G, Speranza N, Casas M, Arrieta F, Camou T, Rosa R, De Oliveira LH, Verani JR. Effectiveness of the 7-valent pneumococcal conjugate vaccine against vaccine-type invasive disease among children in Uruguay: an evaluation using existing data. Vaccine 2013;31 Suppl 3:C109-13. [PMID: 23777683 DOI: 10.1016/j.vaccine.2013.01.059] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
11 Nuorti JP, Martin SW, Smith PJ, Moran JS, Schwartz B. Uptake of Pneumococcal Conjugate Vaccine Among Children in the 1998–2002 United States Birth Cohorts. American Journal of Preventive Medicine 2008;34:46-53. [DOI: 10.1016/j.amepre.2007.09.028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
12 Snedecor SJ, Strutton DR, Ciuryla V, Schwartz EJ, Botteman MF. Transmission-dynamic model to capture the indirect effects of infant vaccination with Prevnar (7-valent pneumococcal conjugate vaccine (PCV7)) in older populations. Vaccine 2009;27:4694-703. [PMID: 19520197 DOI: 10.1016/j.vaccine.2009.05.062] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
13 O'Brien KL, Levine OS. Effectiveness of pneumococcal conjugate vaccine. Lancet 2006;368:1469-70. [PMID: 17071264 DOI: 10.1016/S0140-6736(06)69614-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
14 Thoon KC, Chong CY, Tee NWS. Early impact of pneumococcal conjugate vaccine on invasive pneumococcal disease in Singapore children, 2005 through 2010. International Journal of Infectious Diseases 2012;16:e209-15. [DOI: 10.1016/j.ijid.2011.11.014] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
15 Temple B, Toan NT, Uyen DY, Balloch A, Bright K, Cheung YB, Licciardi P, Nguyen CD, Phuong NTM, Satzke C, Smith-Vaughan H, Vu TQH, Huu TN, Mulholland EK. Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial. BMJ Open 2018;8:e019795. [PMID: 29884695 DOI: 10.1136/bmjopen-2017-019795] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
16 Trück J, Pollard AJ. Challenges in immunisation against bacterial infection in children. Early Hum Dev 2010;86:695-701. [PMID: 20851537 DOI: 10.1016/j.earlhumdev.2010.08.010] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
17 Otczyk DC, Cripps AW. Vaccination for the control of childhood bacterial pneumonia - Haemophilus influenzae type b and pneumococcal vaccines. Pneumonia (Nathan) 2013;2:2-15. [PMID: 31463182 DOI: 10.15172/pneu.2013.2/229] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.2] [Reference Citation Analysis]
18 Conklin L, Loo JD, Kirk J, Fleming-Dutra KE, Deloria Knoll M, Park DE, Goldblatt D, O'Brien KL, Whitney CG. Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children. Pediatr Infect Dis J 2014;33 Suppl 2:S109-18. [PMID: 24336053 DOI: 10.1097/INF.0000000000000078] [Cited by in Crossref: 60] [Cited by in F6Publishing: 35] [Article Influence: 8.6] [Reference Citation Analysis]
19 Pelton SI, Weycker D, Klein JO, Strutton D, Ciuryla V, Oster G. 7-Valent pneumococcal conjugate vaccine and lower respiratory tract infections: Effectiveness of a 2-dose versus 3-dose primary series. Vaccine 2010;28:1575-82. [DOI: 10.1016/j.vaccine.2009.11.053] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 2.2] [Reference Citation Analysis]
20 Black S, Eskola J, Whitney C, Shinefield H. Pneumococcal conjugate vaccine and pneumococcal common protein vaccines. Vaccines. Elsevier; 2008. pp. 531-67. [DOI: 10.1016/b978-1-4160-3611-1.50027-1] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
21 Komakhidze T, Hoestlandt C, Dolakidze T, Shakhnazarova M, Chlikadze R, Kopaleishvili N, Goginashvili K, Kherkheulidze M, Clark A, Blau J. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia. Vaccine 2015;33:A219-26. [DOI: 10.1016/j.vaccine.2014.12.070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
22 Hanquet G, Valenciano M, Simondon F, Moren A. Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 2013;31:5634-42. [DOI: 10.1016/j.vaccine.2013.07.006] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 9.0] [Reference Citation Analysis]
23 Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark A, Mounaud B, Blau J, Hoestlandt C, Kaić B. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia. Vaccine 2015;33:A209-18. [DOI: 10.1016/j.vaccine.2014.12.043] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
24 Khoshdel A, Rastabi RI, Doosti A, Askari S, Hafizi M. Prevalence of Heptavalent Vaccine-related Pneumococcal Serotypes in Nasopharyngeal carrier in children under five years old in Shahrekord, Iran by Multiplex-PCR during 2010- 2011. J Clin Diagn Res 2014;8:PC01-4. [PMID: 25584276 DOI: 10.7860/JCDR/2014/8970.5104] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
25 Tashani M, Jayasinghe S, Harboe ZB, Rashid H, Booy R. Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction. World J Clin Pediatr 2016; 5(3): 311-318 [PMID: 27610348 DOI: 10.5409/wjcp.v5.i3.311] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Sibak M, Moussa I, El-tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, Hajjeh R, Munier A. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013. Vaccine 2015;33:A182-91. [DOI: 10.1016/j.vaccine.2014.12.044] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
27 Jardine A, Menzies RI, Deeks SL, Patel MS, McIntyre PB. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J 2009;28:761-5. [PMID: 19546840 DOI: 10.1097/INF.0b013e31819e9bc5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 7] [Article Influence: 3.2] [Reference Citation Analysis]
28 De Serres G, Pilishvili T, Link-Gelles R, Reingold A, Gershman K, Petit S, Farley MM, Harrison LH, Lynfield R, Bennett NM. Use of surveillance data to estimate the effectiveness of the 7-valent conjugate pneumococcal vaccine in children less than 5 years of age over a 9 year period. Vaccine. 2012;30:4067-4072. [PMID: 22525797 DOI: 10.1016/j.vaccine.2012.04.017] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
29 Jardine A, Menzies RI, McIntyre PB. Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia. Pediatr Infect Dis J 2010;29:607-12. [PMID: 20589980 DOI: 10.1097/inf.0b013e3181d7d09c] [Cited by in Crossref: 80] [Cited by in F6Publishing: 29] [Article Influence: 7.3] [Reference Citation Analysis]
30 Chiu C, Ridley G, Menzies R, Mcintyre P. Update on childhood pneumococcal vaccination. Pediatric Health 2008;2:351-65. [DOI: 10.2217/17455111.2.3.351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
31 Domínguez A, Ciruela P, García-garcía JJ, Moraga F, Sevilla MFD, Selva L, Coll F, Muñoz-almagro C, Planes AM, Codina G, Jordán I, Esteva C, Hernández S, Soldevila N, Cardeñosa N, Batalla J, Salleras L. Effectiveness of 7-valent pneumococcal conjugate vaccine in the prevention of invasive pneumococcal disease in children aged 7–59 months. A matched case-control study. Vaccine 2011;29:9020-5. [DOI: 10.1016/j.vaccine.2011.09.034] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
32 Whitney CG, Moore MR. Direct and Indirect Effectiveness and Safety of Pneumococcal Conjugate Vaccine in Practice. In: Siber GR, Klugman KP, Helena Mäkelä P, editors. Pneumococcal Vaccines. Washington: ASM Press; 2008. pp. 351-68. [DOI: 10.1128/9781555815820.ch24] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
33 Andrews N, Waight PA, Borrow R, Ladhani S, George RC, Slack MP, Miller E. Using the indirect cohort design to estimate the effectiveness of the seven valent pneumococcal conjugate vaccine in England and Wales. PLoS One 2011;6:e28435. [PMID: 22164292 DOI: 10.1371/journal.pone.0028435] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 4.8] [Reference Citation Analysis]